NICM
BEAM icon

Neo Ivy Capital Management’s Beam Therapeutics BEAM Stock Holding History

Neo Ivy Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,698
Closed -$498K – 410
2022
Q1 		$498K Buy
+8,698
New +$570K 0.45% 72
2021
Q3 		– Sell
-982
Closed -$126K – 468
2021
Q2 		$126K Sell
982
-112
-10% -$8.92K 0.13% 234
2021
Q1 		$88K Buy
+1,094
New +$104K 0.1% 262

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Neo Ivy Capital Management's BEAM Position: Q2 2022 in Review

Neo Ivy Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 8,698 shares — an estimated $498K sold.

Neo Ivy Capital Management first reported a position in BEAM in Q1 2021 and held it in 3 quarters. The position peaked at $498K in Q1 2022. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • Neo Ivy Capital Management reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Neo Ivy Capital Management sold 8,698 Beam Therapeutics shares in Q2 2022, an estimated $498K.
  • Neo Ivy Capital Management first reported a position in Beam Therapeutics in Q1 2021 and held it in 3 quarters.
  • Neo Ivy Capital Management's Beam Therapeutics position peaked at $498K in Q1 2022.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on Neo Ivy Capital Management's 13F filing for Q2 2022, filed 16 Aug 2022.